See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Social Media
Trade War
Donald Trump
Natural Disasters
Artificial Intelligence
Trade
Stock Markets
European Union
Baseball
Education
Senate
Published • loading... • Updated

Trial Data Shed Light on ALS Clinical Research

Summary by MedPage Today
(MedPage Today) -- The phase III trial COURAGE-ALS of investigational reldesemtiv, a fast skeletal troponin activator, did not meet its primary endpoint in amyotrophic lateral sclerosis (ALS), but its findings shed light on ALS clinical research...

6 Articles

All
Left
Center
1
Right
MedPage TodayMedPage Today
Reposted by
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News
Center

Trial Data Shed Light on ALS Clinical Research

(MedPage Today) -- The phase III trial COURAGE-ALS of investigational reldesemtiv, a fast skeletal troponin activator, did not meet its primary endpoint in amyotrophic lateral sclerosis (ALS), but its findings shed light on ALS clinical research...

·New York, United States
Read Full Article
ALS News TodayALS News Today

Health Canada set to consider early approval of PrimeC for ALS

Health Canada has invited Neurosense Therapeutics to discuss the potential for giving conditional approval to PrimeC in treating amyotrophic lateral sclerosis (ALS), according to a company filing with the U.S. Securities and Exchange Commission. The upcoming meeting provides an opportunity to consider if the drug is eligible for Health Canada’s Notice of Compliance with Conditions pathway, which applies to medications expected to offer a signifi…

Read Full Article
neurologylive.comneurologylive.com

Short-Term Analysis Confirms Safety of Oral Edaravone in ALS Over 96 Weeks

Results from a recent phase 3 study presented at the 2025 MDA Conference reported that oral edaravone remained well tolerated in patients with ALS over 96 weeks, with no new safety concerns.

Read Full Article
StockheadStockhead

Break it Down: One step closer to treating ALS

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Tylah Tully gives the skinny on Neurizon Therapeutics (ASX:NUZ) HEALEY ALS Platform Trial, as the company makes progress developing its lead asset NUZ-001. Tune in to get the latest. The post Break it Down: One step closer to treating ALS appeared first on Stockhead.

Read Full Article
themarketonline.com.authemarketonline.com.au

'Maximising the potential': Neurizon prepares for HEALEY study of ALS

Neurizon Therapeutics (ASX:NUZ) has shared an update on its preparations for its HEALEY ALS Platform Trial – a multicentre, double-blind, adaptive study that will assess the safety and efficacy of various investigational products for treatment of amyotrophic lateral sclerosis (ALS). Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. The headlin…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

themarketonline.com.au broke the news in on Monday, March 24, 2025.
Sources are mostly out of (0)

Similar News Topics

Health Canada

Health Canada

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal